Phase II Study of Safety and Efficacy of Dasatinib in Patients with Chronic Phase Chronic Myelogenous Leukemia achieving a Major Molecular Response on Imatinib.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Mar 2015
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 30 May 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 05 Mar 2012 New trial record